Arcus Biosciences enters its third-quarter report with a striking disconnect. Three months ago management sounded more confident than at any point in the past year, lifting revenue guidance for a third straight time and describing a clear path for casdatafan to become the backbone of kidney cancer treatment across every line of therapy. Since then, the stock has lost nearly 40% while the S&P 500 was essentially flat. The report on November 4, after the close, is the first chance for management to defend that bullish narrative on an earnings stage, and the numbers themselves will matter far less than what the company says about its lead drug.
On paper, Wall Street expects a loss of $0.92 per share, an improvement of roughly 28% from the $1.27 loss a year ago but wider than the $0.72 loss in the second quarter. Revenue is forecast at just $11.9 million, down about 54% from last year and a steep drop from $41.0 million last quarter. That sequential slide is not a surprise. Arcus collects collaboration revenue rather than product sales, and management flagged on its last call that the wind-down of the Gilead program in lung cancer would pressure reported revenue going forward. The more interesting wrinkle is the annual outlook. Management now guides to $65 million to $75 million for 2026, up from $50 million to $65 million in the spring and $45 million to $55 million at the start of the year, yet the Street sits near $78 million, above the top of that range. Analysts appear to be leaning on further upward revisions, so a reaffirmation rather than another raise could read as a modest letdown, even though the revenue line has little bearing on the long-term value of a clinical-stage biotech.
The real test is casdatafan. Last quarter Arcus framed the drug's peak sales potential at $5 billion to $10 billion, cited a first-line opportunity above $4 billion, and pointed to Merck's frontline failure with belzutifan as clearing the competitive field. Management also promised a large October investor event with data on more than 200 patients across first-line, second-line and late-line settings, including the first overall survival reads. That event falls between the last report and this one, so the call becomes the venue for investors to probe how the company interprets those results, how the frontline triplet is holding up on safety and tolerability, and whether survival trends support the cross-trial comparisons that underpin much of the bullish case.
Validation would look like firm confirmation that the PEAK 20 frontline Phase III trial combining casdatafan with ipilimumab and nivolumab will start by year-end as planned, that PEAK 1 remains on pace for full enrollment by the end of 2026, and that the three no-cost collaborations signed this summer with BMS, Summit and Aveo are moving ahead. Any slippage in those timelines, a softer tone on the triplet, or new pipeline pruning would challenge the story management built over the past several quarters. Early immunology progress, including pharmacokinetic data for AB102 expected in the fourth quarter, is a secondary item.
Cash is the other swing factor. Holdings fell from $1.0 billion at the end of 2025 to $775 million by June, tracking toward a roughly $600 million year-end target with runway into at least the second half of 2028. Investors should check that burn stays on that glide path, especially with a new Phase III starting and more than 80% of portfolio spending shifting to casdatafan.
Sentiment has soured, with bearish readings climbing to about 42% from 28% ahead of the prior report. The stock, at $17.76, sits well below its 200-day moving average near $24.72 and just above its post-earnings low of $17.43, a sharp reversal from a range that peaked above $31. That leaves expectations deflated. The central question is whether management can convincingly argue that casdatafan's frontline opportunity remains as large and as reachable as it claimed three months ago. If it can, the selloff may look overdone; if not, the market's skepticism will have been vindicated.